Search

Your search keyword '"Anja Vogt"' showing total 103 results

Search Constraints

Start Over You searched for: Author "Anja Vogt" Remove constraint Author: "Anja Vogt"
103 results on '"Anja Vogt"'

Search Results

1. The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment

2. Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

3. Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance

4. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

7. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

8. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

10. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

11. Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

12. Therapieempfehlungen bei Fettstoffwechselstörungen: Die neue Leitlinie von 2019

14. The German CaRe High Registry for Familial Hypercholesterolemia –Sex Differences, Treatment Strategies and Target Value Attainment

16. Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis

17. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report

19. Lipoprotein(a)—antisense therapy

20. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

21. [Management of dyslipidaemias: The New 2019 ESC/EAS-Guideline]

22. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

24. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry

25. Autosomal Recessive Hypercholesterolemia

26. The German Lipoprotein Apheresis Registry (GLAR) – more than 7 years on

27. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)

28. Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands

29. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study

30. Effects of Temperature and Extraction Time on Avocado Flesh (Persea americana) Total Phenolic Yields Using Subcritical Water Extraction

31. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

32. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

33. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency

34. Corrigendum to: 'Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)' [Atherosclerosis 259 (2017 Apr) 20-25]

35. P1703German lipoprotein apheresis registry-more than 5 years on

36. Reply to: 'Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study'

38. Hypercholesterinämie – wann und wie behandeln?

39. Organophosphorus insecticides in honey, pollen and bees (Apis mellifera L.) and their potential hazard to bee colonies in Egypt

40. The genetics of familial hypercholesterolemia and emerging therapies

41. Lipoprotein(a)-apheresis in the light of new drug developments

42. Erratum to: The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

43. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on

44. Hyperlipoproteinaemia(a) - apheresis and emerging therapies

45. Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance

46. Session 2. Cells, materials and biochemistry I

47. Historical trends of inorganic and organic fluorine in sediments of Lake Michigan

48. Zwei Formen familiärer Hypercholesterinämie: Unterschiede bei kardiovaskulären Risikofaktoren sowie kardialer und extrakardialer Atherosklerose

49. Das deutsche Lipoproteinaphereseregister (DLAR) – Was sind die Hintergründe?

50. Schwere, asymptomatische Hypercholesterinämie im jungen Lebensalter

Catalog

Books, media, physical & digital resources